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Abstract 
Background   
Tranexamic acid (TXA) reduces blood transfusion in surgery but the extent of the reduction in blood 
loss and how it relates to the dose of TXA is unclear.   
Methods  
A systematic review of randomised trials was performed. Data were extracted on blood loss from 
trials comparing intravenous TXA with no TXA or placebo in surgical patients. A Bayesian linear 
regression was used to describe the relationship between the reduction in blood loss with TXA and 
the extent of bleeding as measured by the mean blood loss in the control group. A meta-analysis of 
the log-transformed data was conducted to quantify the effect of TXA on blood loss, stratified by 
type of surgery, timing of TXA administration and trial quality.  Meta-regression was used to explore 
the effect of TXA dose. 
Results   
Data from 104 trials were examined. Although the absolute reduction in blood loss with TXA 
increased as surgical bleeding increased, the percentage reduction was similar. TXA reduced blood 
loss by 34% (pooled ratio=0.66, 95% CI 0.65 to 0.67; P<0.001). The percentage reductions in blood 
loss with TXA differed by type of surgery, timing of TXA administration and trial quality but the 
differences were small.  The effect of TXA on blood loss did not vary over the range of doses 
assessed (5.5 to 300 mg/kg).  
Conclusions 
TXA reduces blood loss in surgical patients by about a third. A total dose of 1g appears to be 
sufficient for most adults. There is no evidence to support the use of high doses.  
 
 Introduction 
Tranexamic acid (TXA) reduces the probability of receiving a blood transfusion in surgery.  A 
systematic review of randomised controlled trials showed that TXA reduces the probability of blood 
transfusion by 38% (pooled risk ratio=0.62, 95% CI 0.58 to 0.65; P<0.001)[1].  However, the extent to 
which TXA reduces surgical bleeding and its relationship with the dose of TXA and type of surgery 
remains uncertain.  Because the decision to transfuse depends on factors other than blood loss, the 
effect on blood transfusion may not be an accurate indicator of the effect of TXA on surgical 
bleeding.   
Clinical trials of TXA in surgery usually report the mean blood loss in each group. Previous systematic 
reviews have combined these data to obtain the average difference in mean blood loss between the 
TXA and control groups. However, the usefulness of such a measure is questionable.  It would be 
surprising if TXA reduced blood loss by the same volume in surgical procedures that involve different 
amounts of bleeding.  On the other hand, it may be reasonable to expect a similar percentage 
reduction in blood loss with TXA.   
The objective of this study is to examine whether the effect of TXA on blood loss varies with the 
extent of surgical bleeding. The magnitude of the percentage reduction in blood loss with TXA is 
estimated and how the effect varies by type of surgery, timing of TXA administration, trial quality, 
and dose is assessed.  
Methods 
A systematic review of randomised controlled trials of TXA in surgical patients was conducted.  The 
methods used to identify trials for the review are described in detail elsewhere[1]. In brief, a 
comprehensive search was undertaken for all randomised controlled trials comparing intravenous 
TXA with placebo or no intervention in elective or emergency surgery. Two authors screened the 
search output and the full texts of all eligible trials were obtained.  Information was extracted on 
patient characteristics, type of surgery, dose and timing of TXA administration and average blood 
loss (mean and standard deviation).  The risk of bias associated with sequence generation, allocation 
concealment, blinding, and the completeness of outcome data was assessed for each trial.  
Data analysis 
To explore the relationship between the reduction blood loss with TXA and the extent of bleeding, 
for each trial the mean blood loss in the TXA group was plotted against the mean blood loss in the 
control group.  This relationship was examined using a linear regression estimated using a Bayesian 
model as proposed by Thompson et al[2] to account for random sampling error in the estimates of 
the regression variables (i.e. in the sample means from each trial). Statistical details of the model are 
given in Supplementary File 1.   
To quantify the effect of TXA on the percentage reduction in blood loss, a meta-analysis using both 
fixed and random effects models was conducted. For the purpose of the meta-analysis, blood loss 
data were log transformed and the analysis conducted using the transformed values. The formulae 
used for the transformations are given in Supplementary File 1. A meta-analysis (using arithmetic 
means) of the differences in means using the transformed blood loss data corresponds to a meta-
analysis (using geometric means) of the ratio of means in the original scale. The pooled estimates 
were back-transformed to give the blood loss ratios and 95% confidence intervals on the original 
scale.  Statistical heterogeneity was examined by visual inspection of forest plots, the I2 statistic and 
the χ2 test. 
Subgroup analyses were undertaken to assess the effect of TXA by the type of surgery, timing of TXA 
administration (pre-incision, post-incision), allocation concealment (adequate, unclear, inadequate) 
and type of comparator (placebo or no intervention). Heterogeneity between subgroups was 
assessed using the χ2 test (fixed effect analysis only). Finally, a random effects meta-regression was 
carried out to investigate the association between the effect of TXA on blood loss and the total dose 
of TXA (mg/kg) as a continuous variable. If a fixed dose was used in the trials (e.g. 1000mg) it was 
converted to mg/kg by dividing by 70kg. A funnel plot was inspected for the presence of small study 
effects.  We used STATA (version 12)[3] statistical software for all analyses.    
Results  
Figure 1 shows the trial selection process.  One hundred and twenty-nine randomised controlled 
trials were identified.  The characteristics of the included trials are summarised in Supplementary 
File 2.  Nine reports described multi-arm trials involving a total of 23 eligible pair-wise comparisons; 
each of these was included in the analysis as separate trials. One hundred and four randomised 
comparisons described in 90 articles, reported data on blood loss in a format suitable for this 
analysis[4-93].  These trials involved a total of 8030 patients, 4224 received TXA and 3806 received a 
placebo or no intervention.   
The trials involved cardiac (n=54), orthopaedic (n=33), obstetric & gynaecological (n=7), head & neck 
(n=7), breast cancer (n=1), hepatic (n=1) and urological (n=1) surgery. Eighty trials gave TXA prior to 
surgical incision and 24 trials gave TXA after incision. Thirty-three trials were assessed as being 
adequately concealed (low risk of bias), five trials as inadequately concealed (high risk of bias).  The 
remaining 66 trials presented insufficient information on allocation concealment to allow judgement 
and were rated as unclear. Seventy-five trials were placebo-controlled, whereas a no intervention 
group was used as the control in the remaining 29 trials. 
Effect of TXA on blood loss 
Figure 2 shows the relationship between mean blood loss in the TXA group and mean blood loss in 
the control group. The mean blood loss in the TXA group increased as the mean blood loss in the 
control group increased, but to a lesser extent. The intercept of the regression line (dotted line) 
estimated by the Bayesian model was 4 ml (95% credibility interval -8 ml to 18 ml), a negligible value 
in the context of the observed blood loss estimates.  The Bayesian model corresponded closely with 
the regression line predicted assuming a constant percentage reduction in blood loss (dashed line) 
and an intercept of zero.  
Figure 3 shows the summary results of a fixed effect meta-analysis of the percentage reduction in 
blood loss with TXA.  A forest plot showing the estimates from each trial is shown in Supplementary 
File 3.  The back-transformed pooled ratio of blood loss with TXA was 0.66 (95% CI 0.65 to 0.67; 
P<0.001) indicating that TXA reduced blood loss by 34%. There was substantial statistical 
heterogeneity between trials (I2=83%). There was heterogeneity in the magnitude of effect by type 
of surgery although the extent of the variation was small. All of the subgroup estimates were 
consistent with a reduction in blood loss, and all but one was statistically significant at the 5% level.  
TXA had a greater effect on blood loss when given after incision, although the difference between 
the pre and post-incision estimates was small.  There was heterogeneity in the magnitude of effect 
by adequacy of allocation concealment.  When the analysis restricted to the 33 adequately 
concealed trials, TXA reduced blood loss by 30% (0.70, 95% CI 0.68 to 0.72; P<0.001).  There was no 
evidence for heterogeneity in the estimated effects of TXA when compared to a placebo or a no 
intervention control group. The results from random effects meta-analyses were similar to the fixed 
effect analyses and are shown in Supplementary File 4. 
A fixed dose was converted to the equivalent mg/kg dose in 21 trials.  The total dose of TXA used in 
the trials ranged from 5.5mg/kg to 300mg/kg.  The median dose was 22mg/kg with the majority of 
trials (70%) using a total dose of 30mg/kg or less. Results from the meta-regression suggested that 
the effect of TXA on blood loss did not vary over the dose range assessed (coefficient=0.889, 95% CI 
0.787 to 1.004; P=0.059).  
There was no clear asymmetry in the funnel plot (Figure 4).  
Discussion  
Tranexamic acid reduces surgical blood loss by about a third. Although the magnitude of the 
reduction differs by type of surgery and timing of TXA administration, the differences are small and 
are unlikely to be clinically important.  A total dose of 1g is likely to be sufficient for most adults and 
there is no evidence to support the use of high doses.  
The validity of these results depends on the quality of the included trials and many were of low 
quality. Less than a third of trials were judged to be at low risk of bias on the basis of allocation 
concealment.  Nevertheless, even when the analysis was restricted to adequately concealed trials, 
the effect of TXA on blood loss remained large and highly statistically significant. 
Statistical heterogeneity between trials was substantial and was not explained by type of surgery, 
trial quality, the timing of TXA administration or dose. Differences in the methods used to estimate 
blood loss, the duration over which blood loss was measured, and other aspects of trial quality may 
explain some of the heterogeneity.   
The subgroup analyses showed that the effect of TXA on blood loss varied by type of surgery, trial 
quality and timing of TXA.  However, the extent of the variation was small and the clinical 
importance of such small variations is questionable.   
There was no obvious asymmetry in the funnel plot, but reporting bias remains a concern 
particularly as about one fifth of trials were not included in the analysis due to unsuitable data or 
inadequate reporting.  If many of these or other unpublished trials, showed little or no effect of TXA 
on blood loss, the analysis would have overestimated the treatment effect. Although, in 
consideration of the magnitude and precision of the effect, it is unlikely that any such bias would 
account for all of the observed effect.   
The reduction in bleeding with TXA is almost identical to the reduction in the risk of receiving a 
blood transfusion with TXA suggesting that in surgery, transfusion may be closely titrated to blood 
loss. This might not be the case in trauma patients. The CRASH-2 trial found that early administration 
of TXA reduced the risk of death due to bleeding by about one third but there was no clear reduction 
in the risk of receiving a blood transfusion[94, 95].  
Although there is reliable evidence that TXA reduces bleeding and blood transfusion in surgery, its 
effect on other important outcomes including death and thromboembolic events remains 
uncertain[1].  There is no evidence that it increases the risk of thromboembolic events but it is a 
theoretical concern that may deter some surgeons from using TXA. These uncertainties need to be 
resolved before TXA can be recommended for routine use in surgery.   
The apparent lack of a dose-response relationship across the range of doses examined (5.5 to 300 
mg/kg) has important implications for the use of TXA in surgery.  TXA crosses the blood brain barrier 
and there is some evidence from observational studies of patients undergoing cardiac surgery that 
high-dose TXA (≥100 mg/kg) may cause seizures[96, 97]. Our results imply that the clinical benefit of 
TXA on bleeding can be achieved at doses much lower than those associated with such adverse 
effects.   Indeed, a total dose of about 14 mg/kg (or about 1g in adults) appears to be sufficient for 
most patients.   
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